ArticleTargeted oncology2025

Real-World Outcomes of T790M Mutation Testing and Sequential Osimertinib in EGFR-Positive Advanced Non-small Cell Lung Cancer: A Revisited Strategy.

Kelvin Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.